A perioperative study in patients with non-enhancing, IDH1-mutated, low-grade gliomas is being conducted to determine the concentration of ivosidenib and 2-HG in tumors following presurgical treatment with ivosidenib (clinicaltrials.gov NCT03343197). The gene discussed is IDH1; the disease is central nervous system cancer.